News

hemotune AG appoints a new Chief Business Officer

At the interface of MedTech and Pharma, hemotune AG is engineering a world‑leading magnetic nanoparticle platform to transform separation across the medical value chain – and beyond. 📢 Today, we are delighted to announce that Christian Brühlmann has joined hemotune as Chief Business Officer. With this appointment, our C‑level expands to...

read more

ImmunOs Therapeutics Appoints Dr. Hilmar Ebersbach as Chief Executive Officer

Schlieren, Switzerland, January 5, 2026- ImmunOs Therapeutics AG is pleased to announce that Hilmar Ebersbach, former Chief Scientific Officer of the Company, has been nominated as Chief Executive Officer, effective January 2026. Hilmar brings deep scientific expertise, a strong track record in drug discovery including translational development as well as...

read more

KUORI Enters B2C with Filament Built for Next-Gen Makers

Zurich, Switzerland – 05. December 2025 A game changer for the next generation of circular makers: Swiss cleantech startup KUORI is shaking up the world of material and product design with the launch of a 3D printing filament based on its flagship material BIOWA, a bio-based, biodegradable and recyclable thermoplastic...

read more

Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week Meeting

Schlieren / Zurich, Switzerland, 7 November, 2025 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces that it has presented long term follow-up data from its Phase II SAFE KIDNEY trial of therapeutic antibody potravitug for the...

read more